<?xml version="1.0" encoding="UTF-8"?>
<p>Influenza vaccination can reduce medical expenses imposed by influenza itself and associated acute exacerbations of chronic diseases, which has significant cost effect in elderly patients with underlying diseases. In 2003, the Beijing Municipal Center for Disease Control and Prevention analyzed the efficacy and cost‐benefit analysis of influenza vaccination in 665 people aged over 60 years in Beijing and found that the cost‐benefit ratio was 1.51, which is higher than that of the general population.
 <xref rid="agm212102-bib-0024" ref-type="ref">
  <sup>24</sup>
 </xref> Approximately a third of that benefit was due to reduced onset of chronic diseases. Peasah et al
 <xref rid="agm212102-bib-0025" ref-type="ref">
  <sup>25</sup>
 </xref> performed a meta‐analysis of health economic evaluations of influenza vaccination around the world that included both high‐income and middle‐income countries, and concluded that influenza vaccination was cost‐effective. Wang et al
 <xref rid="agm212102-bib-0026" ref-type="ref">
  <sup>26</sup>
 </xref> demonstrated that influenza vaccination reduced hospitalization costs by US $1282.60 compared with patients who had not undergone influenza vaccination.
</p>
